Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 27.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -16,263.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -16,679.8% |
| EPS Diluted | -0.16 | -0.59 | -0.095 | -2.18 |
| % Growth | 72.9% | -520.4% | 95.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |